Scribd Logo
Upload

Welcome to Scribd!

  • 32 views

    Day 4 - Presentasi VTE, Kuliah SM Okt 2012

    Uploaded by

    Maha Satya Dwi Palguna
    DVT and PE are part of a continuum spectrum of the same disease called venous thromboembolism (VTE). They share common risk factors and pathogenic stimuli. Clinical presentation alone is not sufficiently accurate for diagnosis, so validated clinical probability scores are used to guide appropriate diagnostic strategies. The best available supportive diagnostic modalities, such as ultrasound, CT, or MRI, are used to confirm the existence of DVT or PE suggested by the clinical evaluation and probability score.

    Copyright:

    © All Rights Reserved
    Download as PPT, PDF, TXT or read online from Scribd

    Day 4 - Presentasi VTE, Kuliah SM Okt 2012

    Uploaded by

    Maha Satya Dwi Palguna
    32 views35 pages
    DVT and PE are part of a continuum spectrum of the same disease called venous thromboembolism (VTE). They share common risk factors and pathogenic stimuli. Clinical presentation alone is not sufficiently accurate for diagnosis, so validated clinical probability scores are used to guide appropriate diagnostic strategies. The best available supportive diagnostic modalities, such as ultrasound, CT, or MRI, are used to confirm the existence of DVT or PE suggested by the clinical evaluation and probability score.

    Original Title

    Day 4 - Presentasi VTE, Kuliah Sm Okt 2012

    Copyright

    © © All Rights Reserved

    Available Formats

    PPT, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    DVT and PE are part of a continuum spectrum of the same disease called venous thromboembolism (VTE). They share common risk factors and pathogenic stimuli. Clinical presentation alone is not sufficiently accurate for diagnosis, so validated clinical probability scores are used to guide appropriate diagnostic strategies. The best available supportive diagnostic modalities, such as ultrasound, CT, or MRI, are used to confirm the existence of DVT or PE suggested by the clinical evaluation and probability score.

    Copyright:

    © All Rights Reserved
    Download as PPT, PDF, TXT or read online from Scribd
    Download as ppt, pdf, or txt
    32 views35 pages

    Day 4 - Presentasi VTE, Kuliah SM Okt 2012

    Uploaded by

    Maha Satya Dwi Palguna
    DVT and PE are part of a continuum spectrum of the same disease called venous thromboembolism (VTE). They share common risk factors and pathogenic stimuli. Clinical presentation alone is not sufficiently accurate for diagnosis, so validated clinical probability scores are used to guide appropriate diagnostic strategies. The best available supportive diagnostic modalities, such as ultrasound, CT, or MRI, are used to confirm the existence of DVT or PE suggested by the clinical evaluation and probability score.

    Copyright:

    © All Rights Reserved
    Download as PPT, PDF, TXT or read online from Scribd
    Download as ppt, pdf, or txt
    of 35

    DIAGNOSIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM

    K Suega Hematology Medical Oncology Division Udayana Medical School, Bali

    DVT and PE : a CONTINOUS SPECTRUM OF THE SAME DISEASE call VENOUSTHROMBOEMBOLISM (VTE). REPRESENT A SIGNIFICANT HEALTH PROBLEM because of ITS HIGH MORBIDITY and MORTALITY and MOREOVER CHARACTERIZED BY HIGH RATE OF RECURRENCE VTE : age adjusted INCIDENCE 1-2 EVENT/ 1000 POPULATION
    STARTING FROM CALF DVT EXTENDED TO PROXIMAL DVT and DEVASTATING PE, based on its SEVERITY and the INTENSITY OF PROTHROMBOTIC STIMULUS ACUTE VTE PRESENT EITHER BY LUNG or LEG SYMPTOMS, but MOST PATIENTS HAVE THROMBUS AT BOTH SITE AT THE TIME OF DIAGNOSTIC

    Fabringer etal., ATVB 2009 Kearon et al., Circulation, 2003 Zhu et al., ATVB 2009

    EPIDEMIOLOGY
    VTE DIFFERS SUBSTANTIALLY WORLWIDE,NECROPSY STUDY : 60% HOSPITAL DEATH HAVING PE. USA : 1 CASE /1000 PERSON/YEAR VTE : LOWER IN ASIAN RACES , INCREASE MARKEDLY WITH AGES AND PREGNANCY ( RR 4,29) PE FOUND IN 29-30% OF ALL PX IN MEDICAL INTENSIVE, 27-33% OF CRITICAL CARE PX, 20-26% OF PX WITH BEDREST PULMONARY DISEASE, 48% OF PX AFTER ARTERY BYPASS GRAFT PE WERE FOUND WITH DVT IN 60-80%, 50% WERE ASYMPTOMATIC DVT : 1 PERSON IN 20 DEVELOP DVT IN THE COURSE OF THEIR LIFE, INCREASED TO 20-70% IN HOSPITALISED PX. UP TO 50% OF DVT BECOME PTS, OBESITY INCREASE THE RISK DVT WERE FOUND WITH ASYMPTOMATIC PE IN 40%
    Ramzi et al. Am Fam Phydician,2004 Quellette et al., Medscape , 2011

    Quellette et al., Medscape 2011

    Thrombosis

    LIFEBLOOD THE

    CHARITY

    Venous thromboembolism
    Treatment and secondary prevention

    DVT

    PE

    Deep vein insufficiency

    Pulmonary hypertension

    Death

    Post-thrombotic syndrome

    Chronic PE

    Ulcus cruris

    Deep vein thrombosis

    Common femoral vein

    Thrombus

    Knee

    Proximal Distal

    PATHOGENESIS

    Robert et al., Anesthesiology, 2004

    ETIOLOGY
    PE
    VENOUS STASIS HYPERCUAGULABLE STATE IMMOBILITY SURGERY AND TRAUMA PREGNANCY ORAL CONTRACEPTIVE ESTROGEN REPLACEMENT MALIGNANCY HAREDITARY FACTORS ACUTE MEDICAL ILLNESS

    DVT
    INCREASED BLOOD VISCOUSITY INCREASED CENTRAL VENOUS PRESSURE ANATOMIC VARIANT MECHANICAL INJURY GENETIC FACTORS COMMON RISK FACTORS MEDENOX STUDY
    PRESENCE OF ACUTE ILLNESS AGE OLDER THAN 75 YEARS CANCER HISTORY OF PRIOR VTE

    Alikhan et al., Arch Intern Med, 2004 Ramzi et al., AM Fam Physician ,2004 Rugeri et al., Lancet 2001

    Risk Factors for Venous Thromboembolism Age >40 yr History of venous thromboebolism Surgery requiring >30 min of anesthesia Prolonged immobilization Cerebrovascular accident

    Congestive heart failure


    Cancer Fracture of pelvis, femur, or tibia Obesity Pregnancy or recent delivery Estrogen therapy Inflammatory bowel disease Genetic or acquired thrombophilia Antithrombin III deficiency Protein C deficiency Protein S deficiency Prothrombin G20220A mutation Factor V Leiden Anticardiopilin antibody syndrome Lupus anticoagulant

    PATHOPHYSIOLOGY
    PE
    RESPIRATORY COSENQUENSES
    INCREASED ALV. DEAD SPACE HYPOXEMIA HYPERVENTILATION

    DVT
    VENOUS STASIS RESULTS IN AN INCREASED BLOOD VISCOSITY DECREASED WALL CONTRACTILITY AND VEIN VALVE DYSFUNCTION CHRONIC VENOUS INSUFFICIENCY

    HEMODYNAMIC CONSEQUENSES
    PULMONARY VASC. RESISTENCE RIGHT VENTRICULAR FAILURE

    Glhaber et al.,Circulatin ,2003 Riedei et al.,Postgrad Med,2004 Patel et al., Medscape, 2011

    PHYSICAL EXAMINATION
    PE
    MAY VARY, ATYPICAL MOST PX HAVE NO OBVIOUS SYMPTOMS, SHOCK ( MASSIVE PE) SIGNS OF RHF PIOPED III PLEURITIC CHEST PAIN (66%) DYSPNEU (73%) COUGH (37%) HEMOPTYSIS (13%) (SIGNS&SYMPTOMS CANTCONFIRM, WITHOUT IT COULDNT EXCLUDE PE)

    DVT
    HOMAN SIGN ODEMA PAINFULL TENDERNESS DISCOLORATION OF SKIN PHLEGMASIA CERULEA DOLENS PHLEGMASIA ALBA DOLENS

    ( NO SINGLE OR COMBINED SIGNS &SYMPTOMS IS SIGNIFICANTLY ACCURATE )

    Patel et al., Medscape,2011 Quellette et al., Medscape 2011

    Rules for Predicting the Probability of Embolism* Variable Risk factors Clinical signs and symptoms of deep venous thrombosis An alternative diagnosis deemed less likely than pulmonary embolism Heart rate > 100 beats/min Immobilization or surgery in the previous 4 wk Previous deep venous thrombosis or pulmonary embolism Hemoptysis Cancer (receiving treatment, treated in the past 6 mo or palliative care) Clinical probability Low Intermediate High *Adapted from Wells et al 3.0 3.0 No. of points

    1.5 1.5 1.5 1.0 1.0

    <2.0 2.0-6.0 >6.0

    SUPPORTIVE DIAGNOSTIC MODALITIES


    PE
    CHEST RADIOGRAPHY ECG ECHOCARDIGRAPHY V/Q SCANING CT SCANING MRI ANGIOGRAPHY

    DVT
    COMPRESSIVE SONOGRAPHY IMPEDANCE PLETHYSMOGRAPHY SCINTIGRAPHY CT VENOGRAPHY MRI, NUCLEAR IMAGING VENOGRAPHY

    Quellette et al., PE Work up, Medscape,2011

    LABORATORIUM EVALUATION
    D DIMER TROPONIN BRAIN NATRIURETIC PEPTIDE (BNP) GAS ANALYSE BIOMARKERS FOR VTE OTHER RISK FACTORS

    D-dimer testing has been proposed as a non-invasive, inexpensive, rapid, and simple test in the evaluation of suspected VTE. D-dimer assays detect the presence of plasmin-mediated degradation products of fibrin. Levels increase following a thrombotic event with normalization within 15 to 20 days. Recent trauma or surgery, cancer, intravascular coagulation, serious infection, and other conditions can elevate D-dimer levels so D-dimer assays are typically sensitive but not specific.

    Different D-dimer assays have been developed. There is no standard D-dimer level, the units of measure vary, the data from one test cannot be transferred to another, and each laboratory needs to establish and validate cut-off points for the test(s) they are using.
    Measurement of systemic D dimer, an index of ongoing thrombus formation and lysis, can aid clinical diagnosis in venous thromboembolic conditions.

    Smith et al., Technology Assessment Committee, 2003

    RECOMMENDED DIAGNOSTIC STRATEGIC : DIAGNOSTIC ALGORITHM


    HEMODYNAMIC STATUS CO-MORBIDITIES ONSET OF THE SYMPTOMS AVAILABILITIES

    Riedel, Postgrad Med.,2004

    Suspected Pulmonary Embolism New or worsening dyspnea, chest pain or sustained hypertension without another obvious cause Clinical probability assesment

    Hemodynamically stable

    Hemodynamically unstable

    Low or intermediate clinical probability D-dimer testing

    High clinical Probablility

    Not critically

    Critically ill and high clinical probability

    Multidetector CT available Normal Elavated Multidetector CT

    Multidetector CT available Transthoraric or transesophageal echocardiography

    Pulmonary embolism ruled out

    Negative

    Pulmonary embolism confirmed

    Pulmonary embolism confirmed

    No right ventric -cular dysfunction Search for Alternative diagnosis

    Treatment and secondary prevention of VTE


    VTE event

    Acute

    Continue

    Heparin or LMWH together with a VKA (e.g. warfarin) until an INR of 2.0-3.0 is achieved

    VKA (e.g. warfarin) INR 2.0-3.0

    VTE - treatment options

    Acute

    Long-term

    Anticoagulation - UFH/LMWH Thrombolysis Thrombectomy Inferior vena cava filters (IVCF)

    Anticoagulation - VKAs (e.g. warfarin) - LMWH Stockings

    7th ACCP recommendations - Initial treatment for acute DVT or PE


    Confirmed DVT or non-massive PE Initial treatment with sc LMWH or iv UFH (or sc if DVT)
    [Grade 1A] for at least 5 days [Grade 1C]

    Start VKA with LMWH or UFH on day 1 [Grade 1A] Stop LMWH or UFH when INR stable >2.0 [Grade 1A] High clinical suspicion of VTE
    Anticoagulation until outcome of diagnostic
    tests [Grade 1C+]

    Bller H et al. Chest 2004;126:401S428S

    Treatment and secondary prevention of VTE


    VTE event Decision point

    Acute

    Continue

    How long? 3-6-12 months or lifelong Risk of VTE (5-7%/year) vs. Risk of bleeding (3-4%/year)

    Heparin or LMWH VKA (e.g. warfarin) together with a INR 2.0-3.0 VKA (e.g. warfarin) untill an INR of 2.0-3.0 is achieved

    7th ACCP recommendations - Long-term treatment for DVT or PE


    First episode with a transient risk factor 3 months after distal or proximal DVT [Grade 1A] At least 3 months after PE [Grade 1A]

    First episode of idiopathic DVT/PE VKA for at least 612 months [Grade 1A] but consider indefinite duration [Grade 2A] Two or more episodes of DVT/PE Suggest indefinite treatment [Grade 2A]
    Target INR 2.5 (range 2.03.0) [Grade 1A]

    Bller H et al. Chest 2004;126:401S428S

    Long-term treatment of DVT


    Recurrence rate of VTE in patients with DVT dependent on Underlying risk factors for DVT Duration of treatment
    Decision regarding duration of treatment dependent on Underlying risk factors for DVT Risk of haemorrhage from oral anticoagulation Patient preference Numerous regimens studied to improve benefit of long-term treatment while reducing the dose

    SUMMARY
    DVT AND PE WERE A CONTINOUUM SPECTRUM OF SAME DISEASE WHICH SHARED COMMON RISK FACTORS AS WELL AS PATHOGENIC PROTHROMBOTIC STIMULUS CLINICAL PRESENTATION ALONE INSUFFICIENTLY ACCURATE, THEREFORE INCORPORATING INTO VALIDATED CLINICAL PROBABILITY SCORE LEAD TO MORE APPROPRIATE DIAGNOSTIC STRATEGIES TO ESTABLISH THE DIAGNOSIS OF DVT AND PE BEST CHOSEN AVAILABLE SUPPORTIVE DIAGNOSTIC MODALITIES AID CONFIRMATION THE EXISTENCE OF THE DISEASE (DVT,PE)

    You might also like